Cybin Announces Grant Of U.S. Patent Covering Proprietary Deuterated Psilocybin Analog In Its CYB003 Program
Portfolio Pulse from Happy Mohamed
Cybin Inc. has been granted a U.S. patent for its proprietary deuterated psilocybin analog in the CYB003 program. The patent covers composition of matter claims and treatment methods until 2041. The company's intellectual property portfolio now includes 2 granted U.S. patents and over 50 pending patent applications across 6 patent families. CYB003 is currently being evaluated in a Phase 2 clinical trial for the treatment of major depressive disorder. The company expects to report topline Phase 2 efficacy data for CYB003 in Q3/Q4 2023.
August 15, 2023 | 12:00 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
The granting of the U.S. patent for Cybin's proprietary deuterated psilocybin analog in the CYB003 program could potentially strengthen the company's position in the market and increase investor confidence.
The granting of a patent provides Cybin with exclusive rights to the deuterated psilocybin analog in the CYB003 program until 2041. This could potentially give the company a competitive edge in the market, as it prevents other companies from copying or selling the same product. Additionally, the patent could increase investor confidence in the company, as it demonstrates the company's ability to innovate and protect its intellectual property.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100